Company Website

Contact Information:

Holly Wayne
hwayne@rigel.com
608-852-0739

Jimmy Gilbreath
jgilbreath@rigel.com
224-563-7153

Virtual Exhibit Hall Home

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018.

Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.

Additional Information:

Rigel Regional Contacts

TAVALISSE Together - Patient Support

TAVALISSE Dosing and Administration Guide